2026年5月1日 美国东部时间晚8:47 / 福克斯新闻网
阻断FDA规则的裁决或将引发最高法院关于联邦监管米非司酮使用权的斗争
作者：贾斯敏·贝尔 福克斯新闻网
您现在可以收听福克斯新闻的文章了！
收听全文
时长：4分钟
周五，联邦上诉法院叫停了依照现行美国食品药品监督管理局（FDA）规则邮寄堕胎药米非司酮的行为。法院承认，此举“实际上将产生全国范围的影响”，并可能引发一场围绕堕胎权的最高法院之争。
美国第五巡回上诉法院的这项裁决可能会限制全美范围内的堕胎药获取渠道。支持者称，此举恢复了一项旨在保护患者安全和州权的规定；而批评者警告称，即便在堕胎仍合法的州，民众获取药物的难度也会加大。
这一裁决意味着，女性现在必须亲自就诊才能获得米非司酮处方，恢复了前总统乔·拜登任内新冠疫情期间取消的这项要求。
根据古特马赫研究所的研究，米非司酮是药物流产常用的两种药物之一，占美国堕胎手术的大多数。
堕胎药米非司酮暂可继续邮寄，FDA面临6个月审核期限
法院的禁令阻断了该药物的邮寄分销渠道，实际上叫停了FDA近期规则修改所允许的药房配药方式，要求依照此前的安全协议进行面对面配药。
“正如地区法院所指出的，第705条的暂缓令‘实际上将产生全国范围的影响’，”法院在判决书中写道，直白地阐明了这项裁决的广泛影响。
法官们严厉批评了FDA对该药物安全数据的处理方式，称该机构“此前取消了米非司酮不良事件报告要求”，并指责其先是取消报告要求，随后又以缺乏相关数据为由为扩大准入辩护，此举“不合理”。
该裁决还支持了包括路易斯安那州在内的反堕胎州的论点，这些州认为联邦政策削弱了本州的堕胎法律。
“FDA的每一项堕胎便利措施都抵消了路易斯安那州的堕胎禁令，”法院写道，并补充道，该州的政策承认“每一个未出生的孩子都是人类……从受孕的那一刻起。
共和党参议员谴责FDA扩大堕胎药准入
“一旦失去，这种保护未出生生命的主权特权便无法再恢复。”
这项裁决标志着堕胎药物法律斗争的重大升级，联邦监管机构与那些试图在2022年最高法院推翻罗伊诉韦德案后实施更严格堕胎法律的州形成对立。
反堕胎组织迅速对该裁决表示赞扬。
“这是我们期待已久的胜利，我们祈祷它能维持下去，”学生生命组织主席克里斯滕·霍金斯说道。
“如果支持堕胎的州允许犯罪企业兴起，违反其反堕胎邻州的法律，我们就不能再称自己为美利坚合众国。”
纽约医生因涉嫌通过远程医疗向路易斯安那州患者开具堕胎药被起诉
家庭研究理事会主席托尼·珀金斯称该裁决是“未出生婴儿的好消息”，并补充道，这一问题“很快就应该提交至美国最高法院”。
支持堕胎权的倡导者尖锐批评了这项裁决。
纽约州检察长莉蒂夏·詹姆斯表示，米非司酮“安全、有效且不可或缺”，称该裁决是“又一次对堕胎权的残酷攻击”。
“限制堕胎护理就是限制挽救生命的医疗服务，”她补充道。
正如福克斯新闻数字频道此前报道的那样，上月一名联邦法官曾允许米非司酮暂时继续通过邮寄方式销售，当时法律挑战和联邦审核工作仍在进行中。
多布斯案裁决三年后，反堕胎运动直面高堕胎率
法官戴维·C·约瑟夫此前曾警告“不要通过诉讼进行治理”，强调应由FDA正在进行的安全审核而非诉讼来决定长期政策。
目前审核仍在进行中，美国卫生与公众服务部和FDA负责审查米非司酮的安全数据、不良事件和监管框架。
点击此处下载福克斯新闻APP
路易斯安那州检察长莉兹·穆里尔曾辩称，该政策“每天都在造成无法弥补的伤害”，并警告称，扩大准入的目的是“渗透到路易斯安那州等司法管辖区”，尽管这些州已经实施了堕胎限制。
周五的裁决现在可能会引发向最高法院的上诉，届时一场关于联邦监管堕胎药物权限的新挑战或将成为焦点。
本报道由美联社供稿。
贾斯敏·贝尔是福克斯新闻数字频道突发新闻撰稿人，报道政治、军事、信仰和文化领域新闻。
Federal appeals court blocks mailing of abortion pills in ruling with nationwide effect
May 1, 2026 8:47pm EDT / Fox News
Decision blocking FDA rule sets up a likely Supreme Court fight over federal authority to regulate mifepristone access
By Jasmine Baehr, Fox News
NEW You can now listen to Fox News articles!
Listen to this article
4 min
A federal appeals court on Friday blocked the mailing of the abortion pill mifepristone under current Food and Drug Administration (FDA) rules, a move the court acknowledged would, “as a practical matter, have a nationwide effect,” one that sets up a likely Supreme Court battle over abortion access.
The 5th U.S. Circuit Court of Appeals ruling could restrict abortion pill access across the country, restoring rules supporters say protect patient safety and state authority, while critics warn it will make access harder even in states where abortion remains legal.
The decision means women will now have to see a medical professional to obtain a mifepristone prescription, restoring a requirement that had been lifted during the COVID-19 pandemic under former President Joe Biden.
Mifepristone is one of two drugs commonly used in medication abortions and accounts for a majority of abortions in the U.S., according to research from the Guttmacher Institute.
ABORTION PILL MIFEPRISTONE STAYS AVAILABLE BY MAIL FOR NOW AS FDA FACES 6-MONTH REVIEW DEADLINE
A packet of misoprostol abortion pills.(Sergei Gapon/AFP)
The court’s order blocks mail-order distribution of the drug and effectively halts pharmacy-based dispensing allowed under recent FDA rule changes, requiring it to be dispensed in person under earlier safety protocols.
“It is true, as the district court noted, that a § 705 stay ‘would, as a practical matter, have a nationwide effect.’” the court wrote, putting in plain terms the sweeping implications of the decision.
Judges sharply criticized the FDA’s handling of the drug’s safety data, saying the agency had “previously eliminated the requirement to report mifepristone’s adverse events,” and calling it “unreasonable” to remove reporting requirements and then rely on the resulting lack of data to justify expanded access.
The ruling also sided with arguments from pro-life states, including Louisiana, which said federal policy undermined their abortion laws.
“Every abortion facilitated by FDA’s action cancels Louisiana’s ban,” the court wrote, adding that the state’s policy recognizes “every unborn child is a human being … from the moment of conception.
REPUBLICAN SENATORS BLAST FDA FOR EXPANDING ABORTION PILL ACCESS
Pro-life demonstrators march to the Supreme Court for the annual March for Life in Washington, D.C. in 2025.(Bryan Dozier/Middle East Images/AFP via Getty Images, File)
“Once lost, that sovereign prerogative of protecting unborn life cannot be regained.”
The ruling marks a major escalation in the legal fight over abortion drugs, pitting federal regulators against states seeking to enforce stricter abortion laws after the Supreme Court’s 2022 decision overturning Roe v. Wade.
Pro-life groups quickly praised the decision.
“This is a win we’ve been waiting for, and we pray it holds,” Students for Life President Kristan Hawkins said.
“We can’t remain the United States of America if abortion-loving states allow criminal enterprises to be set up, breaking the laws of their pro-life neighbors.”
NEW YORK DOCTOR INDICTED FOR ALLEGEDLY PRESCRIBING ABORTION PILL TO PATIENT VIA TELEMEDICINE IN LOUISIANA
Boxes of mifepristone used for medical abortions.(Evelyn Hockstein/Reuters, File)
Family Research Council President Tony Perkins called the ruling “great news for the unborn,” adding that the issue “should be before the U.S. Supreme Court soon.”
Pro-choice advocates sharply criticized the decision.
New York Attorney General Letitia James said mifepristone is “safe, effective and essential,” calling the ruling “yet another cruel attack on abortion access.”
“Restrictions on abortion care are restrictions on life-saving health care,” she added.
As Fox News Digital previously reported, a federal judge had allowed mifepristone to remain available by mail on a temporary basis last month while legal challenges and federal review efforts continued.
PRO-LIFE MOVEMENT CONFRONTS HIGH ABORTION RATES THREE YEARS AFTER DOBBS
Pro-life supporters hold signs outside the Supreme Court in Washington, D.C.(Olivier Douliery/AFP via Getty Images, File)
Judge David C. Joseph previously cautioned against “government by lawsuit,” emphasizing that the FDA’s ongoing safety review, not litigation, should determine long-term policy.
That review remains underway, with the Department of Health and Human Services and the FDA tasked with examining safety data, adverse events and the regulatory framework on mifepristone.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Louisiana Attorney General Liz Murrill had argued the policy caused “irreparable harm every day” it remained in place, warning expanded access was designed to “reach into jurisdictions like Louisiana” despite state-level abortion restrictions.
Friday’s ruling now sets up a likely appeal to the Supreme Court, where a new challenge to federal authority over abortion drug regulation could take center stage.
The Associated Press contributed to this reporting.
Jasmine Baehr is a Breaking News Writer for Fox News Digital, where she covers politics, the military, faith and culture.